BRAF is a rare targetable mutation in non-small-cell lung cancer (NSCLC). Emerging evidence underlines that, rather than a single point mutation, BRAF genes present with a wide array of mutations, essentially in lung adenocarcinoma. Different BRAF mutations have divergent clinical and therapeutic implications, with a particular distinction between V600E and non-V600E mutations. The latter are at least as frequent in NSCLC as V600E, but lack any proven targeted therapy. In this paper, we briefly review the current literature and provide an update of scientific knowledge about different types of BRAF mutations in NSCLC
BRAF mutations are seen in up to 3.5–4% of the non-small cell lung cancer (NSCLC) patients. BRAF V60...
B-Raf mutations occur in about 1-2% of non-small cell lung cancers (NSCLC). These mutations generate...
Dear Editor, With great interest we read the paper by Salimian et al. [1], describing the distribu...
BRAF is a rare targetable mutation in non-small-cell lung cancer (NSCLC). Emerging evidence underlin...
Purpose BRAF mutations are found in a subset of non-small cell lung cancers (NSCLCs). We examined t...
BRAF mutations have been well described in non-small cell lung cancer (NSCLC) for several years, but...
Background: BRAF mutations have been well described in non-small cell lung cancer (NSCLC) for severa...
BRAF mutations are known as oncogenic drivers of non-small cell lung cancer (NSCLC). BRAF inhibition...
Background: BRAF is a proto-oncogene encoding a serine/threonine protein kinase which promotes cell ...
Introduction: BRAF mutation involved 2–4% of lung adenocarcinoma. Differences in clinicopathologic f...
Simple Summary Non-small cell lung cancer (NSCLC) patients harboring BRAF non-V600 alterations const...
V-RAF murine sarcoma viral oncogene homolog B1 (BRAF) mutated non-small-cell lung cancer (NSCLC) is ...
Dabrafenib and trametinib are approved for the management of advanced non-small-cell lung cancers (N...
Targeted therapy is one of the major treatment modalities in advanced non-small cell lung cancer (NS...
With the development of precision medicine, therapies of targeting driver genes have significantly p...
BRAF mutations are seen in up to 3.5–4% of the non-small cell lung cancer (NSCLC) patients. BRAF V60...
B-Raf mutations occur in about 1-2% of non-small cell lung cancers (NSCLC). These mutations generate...
Dear Editor, With great interest we read the paper by Salimian et al. [1], describing the distribu...
BRAF is a rare targetable mutation in non-small-cell lung cancer (NSCLC). Emerging evidence underlin...
Purpose BRAF mutations are found in a subset of non-small cell lung cancers (NSCLCs). We examined t...
BRAF mutations have been well described in non-small cell lung cancer (NSCLC) for several years, but...
Background: BRAF mutations have been well described in non-small cell lung cancer (NSCLC) for severa...
BRAF mutations are known as oncogenic drivers of non-small cell lung cancer (NSCLC). BRAF inhibition...
Background: BRAF is a proto-oncogene encoding a serine/threonine protein kinase which promotes cell ...
Introduction: BRAF mutation involved 2–4% of lung adenocarcinoma. Differences in clinicopathologic f...
Simple Summary Non-small cell lung cancer (NSCLC) patients harboring BRAF non-V600 alterations const...
V-RAF murine sarcoma viral oncogene homolog B1 (BRAF) mutated non-small-cell lung cancer (NSCLC) is ...
Dabrafenib and trametinib are approved for the management of advanced non-small-cell lung cancers (N...
Targeted therapy is one of the major treatment modalities in advanced non-small cell lung cancer (NS...
With the development of precision medicine, therapies of targeting driver genes have significantly p...
BRAF mutations are seen in up to 3.5–4% of the non-small cell lung cancer (NSCLC) patients. BRAF V60...
B-Raf mutations occur in about 1-2% of non-small cell lung cancers (NSCLC). These mutations generate...
Dear Editor, With great interest we read the paper by Salimian et al. [1], describing the distribu...